Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Description:
Host: Helena Yu, MD
Guest: Pasi Antero Jänne, MD, PhD
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn. This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a...